Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors

Sorafenib is a multi-kinase small molecule inhibitor that targets serine/threonine and tyrosine kinases including the RAF kinase family, VEGFR-2, and PDGFR. The aim of this study was to evaluate the systemic pharmacokinetics of a previously defined tolerable oral dose of sorafenib in tumor-bearing d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cawley, Jacob R., Stewart, Samuel D., Mochel, Jonathan Paul, Veluvolu, Sridhar, Khanna, Chand, Fenger, Joelle M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Veterinary Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162170/
https://www.ncbi.nlm.nih.gov/pubmed/35664857
http://dx.doi.org/10.3389/fvets.2022.888483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162170/
https://www.ncbi.nlm.nih.gov/pubmed/35664857
http://dx.doi.org/10.3389/fvets.2022.888483

Ejemplares similares